VYGR at a glance
Voyager Therapeutics, Inc. (VYGR, SEC CIK 1640266) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Voyager Therapeutics, Inc. (VYGR) reported revenue of $40.4 million (down 49.5% from FY2024) and a net loss of $119.7 million. Diluted EPS was -$2.04.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Voyager Therapeutics, Inc. (VYGR) shares worth $70.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sandrock Alfred on April 2, 2026 of 11,511 shares at $3.87 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $40.4M
- −49.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $70.4M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New clinical-development risk triggered by FDA IND clearance: VY1706 trial expected to enroll up to 18 patients beginning fourth quarter 2026
- Materially updated collaboration risk: Novartis partial termination ended milestone and royalty eligibility for two programs effective February 1, 2026
- Regulatory risk from first-in-human VY1706 testing: clinical trial includes dose escalation up to 5 × 10^13 vector genomes per kilogram
- Operational risk from limited clinical-stage pipeline: VY1706 dosing expected fourth quarter 2026, with initial safety data anticipated early 2027
- Financial risk from continued funding needs: six-month net loss $52.4 million and accumulated deficit $498.3 million at June 30, 2026
AI summary of the VYGR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $24.5M, or $0.40 per share, improved from $33.4M and $0.57 year over year
- Cash, equivalents and marketable securities $148.8M, funding planned operations into 2028 under current plans
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial and operating results released August 6, 2026
- Press release contains the substantive results and operating updates
Item 8.01: Other Events
- VY1706 GLP toxicology showed favorable tolerability in non-human primates through six months
- No adverse CNS, dorsal root ganglia, or peripheral-organ findings at doses up to 5 × 10¹³ vector genomes/kg
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Authorized capital stock doubled from 125M to 245M shares
- Authorized common stock doubled from 120M to 240M shares
Item 5.07: Submission of Matters to a Vote of Security Holders
- Three Class II directors elected through 2029, preserving board continuity
- Executive compensation advisory proposal approved, with 32,041,373 votes for
AI summaries of VYGR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VYGR
Don't miss the next VYGR filing
- Alerts as it files. A push when VYGR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VYGR, by share count.
- Ask anything. An AI agent that reads every VYGR filing and answers with sources.
VYGR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SCANGOS GEORGE A | A | Jun 9, 2026 | 30,000 | - |
| Higgins Michael J | A | Jun 9, 2026 | 30,000 | - |
| GERAGHTY JAMES A | A | Jun 9, 2026 | 30,000 | - |
| Hyman Steven | A | Jun 9, 2026 | 30,000 | - |
| Onyia Jude | A | Jun 9, 2026 | 30,000 | - |
| PIERCE GLENN | A | Jun 9, 2026 | 30,000 | - |
| MACKEY CATHERINE J | A | Jun 9, 2026 | 30,000 | - |
| Vitale Nancy | A | Jun 9, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $80.0M | $40.4M |
| Operating Income | - | -$83.3M | -$131.8M |
| Net Income | $132.3M | -$65.0M | -$119.7M |
| Op. Margin | - | -104.1% | -326.6% |
| Net Margin | - | -81.3% | -296.5% |
| Balance Sheet | |||
| Total Assets | $351.3M | $393.1M | $252.3M |
| Equity | - | $299.8M | $196.1M |
| ROE | - | -21.7% | -61.1% |
| Per Share | |||
| EPS | $2.97 | $-1.13 | $-2.04 |
| Cash Flow | |||
| Operating CF | - | -$15.3M | -$132.5M |
| CapEx | $3.3M | $3.5M | $2.6M |
Source: XBRL data in Voyager Therapeutics, Inc. (VYGR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VYGR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $70.4M |
| Q1 2026 | 25 | $70.7M |
| Q4 2025 | 23 | $66.5M |
| Q3 2025 | 23 | $82.8M |
| Q2 2025 | 22 | $50.5M |
| Q1 2025 | 19 | $30.3M |
| Q4 2024 | 17 | $41.4M |
| Q3 2024 | 14 | $25.5M |
- Millennium Management+1.01M (+30%)
- Citadel Advisors LLC+419.4K (+115%)
- Two Sigma Investments+332.9K (+54%)
- State Street Corp+128.2K (+14%)
- AQR Capital Management+123.4K (+53%)
- BlackRock−396.3K (-7%)
- Goldman Sachs Group−89.1K (-21%)
- Renaissance Technologies LLC−82.8K (-14%)
- Bank of America Corp−62.2K (-58%)
- Dimensional Fund Advisors−37.4K (-4%)
- StoneX Group Inc.+13.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 169 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VYGR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 3, 2026 | - | - | - |
| 4 | Apr 3, 2026 | - | - | - |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
VYGR SEC filings: frequently asked questions
Which institutions hold VYGR stock?
As of June 30, 2026, the largest Voyager Therapeutics, Inc. (VYGR) holders among the 13F filers tracked by SignalX were BlackRock ($18.1 million), Millennium Management ($15.6 million), Vanguard Capital Management LLC ($8.2 million), State Street Corp ($3.8 million), Two Sigma Investments ($3.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VYGR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Voyager Therapeutics, Inc. (VYGR) reported revenue of $40.4 million (down 49.5% from FY2024) and a net loss of $119.7 million. Diluted EPS was -$2.04. The figures come from the XBRL data in the 10-K.
What did VYGR report in its latest 8-K?
Voyager Therapeutics, Inc. (VYGR) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 net loss $24.5M, or $0.40 per share, improved from $33.4M and $0.57 year over year.
What are the latest VYGR SEC filings?
Voyager Therapeutics, Inc. (VYGR) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on June 11, 2026.
What is VYGR's SEC CIK number?
Voyager Therapeutics, Inc. (VYGR)'s SEC Central Index Key (CIK) is 1640266. EDGAR lists every VYGR filing under that number.
Ask anything about VYGR
The research agent reads VYGR's filings, financials, insider trades and 13F holders, then answers with sources.